English

ProQR Therapeutics N.V.

EDGAR

PRQR Report (type unavailable) · filed 2026-09-23

Annual consolidated revenue for 2025: about Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 15.91M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 18.91M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

8.76 million Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

2026 Q2 · Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

Exact inputs and evidence

Revenue: 8759000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source

Operating margin

-100.72%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -8822000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source
Revenue: 8759000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source

Operating cash flow

-12.3 million Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

2026 Q2 · Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

Exact inputs and evidence

Operating Cash Flow: -12270000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source

Free cash flow

-12.6 million Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

2026 Q2 · Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA

Exact inputs and evidence

Operating Cash Flow: -12270000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source
Capital Expenditure: 291000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA Source

Cash and cash equivalents: 117 million Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA 2026-06-30 Source
Exact value

117125000 Unit_Standard_EUR_gtEttuIdgUmF-VkGC0NZRA
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-23.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-15.9%

Prior period

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 18.91 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 15.91 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

15906000 − 18905000 = -2999000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g

18905000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
15906000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Year-over-year change in Revenue: -2999000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 15906000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#3111352 Filing: 000110465926026713 Input fundies:Revenue: 18905000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#3112239 Filing: 000110465926026713
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 14.42 million

Prior period

−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 27.76 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 42.18 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-42184000 − -27763000 = -14421000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g

-27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Year-over-year change in Net income: -14421000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#1999231 Filing: 000110465926026713 Input fundies:NetIncome: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2000345 Filing: 000110465926026713
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 16.4 million

Prior period

−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 36.39 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 52.79 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-52791000 − -36393000 = -16398000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g

-36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Year-over-year change in Operating cash flow: -16398000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2303580 Filing: 000110465926026713 Input fundies:OperatingCashFlow: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2304445 Filing: 000110465926026713
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-28.1%

Prior period

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.42 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.02 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1020000 − 1418000 = -398000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g

1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Year-over-year change in Capital expenditure: -398000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2309378 Filing: 000110465926026713 Input fundies:CapitalExpenditure: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2310163 Filing: 000110465926026713
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 15.91 million 100% of revenue
Operating costs Derived Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 59.35 million 373% of revenue
Operating income −Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 43.45 million −273% of revenue
Tax, interest and other Derived −Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.26 million −7.9% of revenue
Net income −Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 42.18 million −265% of revenue

Cash

Operating cash flow −Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 52.79 million −332% of revenue
Capital expenditure Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.02 million 6.4% of revenue
Free cash flow Derived −Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 53.81 million −338% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 589% of revenue.
2024 Operating loss: operating costs were 261% of revenue.
2025 Operating loss: operating costs were 373% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	6514000	38373000 Derived	-31859000	-3740000 Derived	-28119000	20177000 Derived	Source 2023-01-01 – 2023-12-31: 6514000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Revenue Open source 2023-01-01 – 2023-12-31: -31859000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -28119000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source 2023-01-01 – 2023-12-31: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	18905000	49377000 Derived	-30472000	-2709000 Derived	-27763000	-37811000 Derived	Source 2024-01-01 – 2024-12-31: 18905000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Revenue Open source 2024-01-01 – 2024-12-31: -30472000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source 2024-01-01 – 2024-12-31: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	15906000	59352000 Derived	-43446000	-1262000 Derived	-42184000	-53811000 Derived	Source 2025-01-01 – 2025-12-31: 15906000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Revenue Open source 2025-01-01 – 2025-12-31: -43446000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source 2025-01-01 – 2025-12-31: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 15.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g)	Source evidence
20232023-12-31	Revenue	6514000	Revenue: 6514000 Open source
20242024-12-31	Revenue	18905000	Revenue: 18905000 Open source
20252025-12-31	Revenue	15906000	Revenue: 15906000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-15.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 6514000 Open source
20242024-12-31	Year over year	190.2%	Revenue: 18905000 Open source Revenue: 6514000 Open source
20252025-12-31	Year over year	-15.9%	Revenue: 15906000 Open source Revenue: 18905000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -273.1% 2025

Net margin -265.2% 2025

Free cash flow margin -338.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-489.1%	Operating Income: -31859000 Open source Revenue: 6514000 Open source
20242024-12-31	Operating margin	-161.2%	Operating Income: -30472000 Open source Revenue: 18905000 Open source
20252025-12-31	Operating margin	-273.1%	Operating Income: -43446000 Open source Revenue: 15906000 Open source
20232023-12-31	Net margin	-431.7%	Net Income: -28119000 Open source Revenue: 6514000 Open source
20242024-12-31	Net margin	-146.9%	Net Income: -27763000 Open source Revenue: 18905000 Open source
20252025-12-31	Net margin	-265.2%	Net Income: -42184000 Open source Revenue: 15906000 Open source
20232023-12-31	Free cash flow margin	309.7%	Revenue: 6514000 Open source Operating Cash Flow: 21548000 Open source Capital Expenditure: 1371000 Open source
20242024-12-31	Free cash flow margin	-200%	Revenue: 18905000 Open source Operating Cash Flow: -36393000 Open source Capital Expenditure: 1418000 Open source
20252025-12-31	Free cash flow margin	-338.3%	Revenue: 15906000 Open source Operating Cash Flow: -52791000 Open source Capital Expenditure: 1020000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g -52.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g)	Source evidence
20232023-12-31	Operating cash flow	21548000	Operating Cash Flow: 21548000 Open source
20242024-12-31	Operating cash flow	-36393000	Operating Cash Flow: -36393000 Open source
20252025-12-31	Operating cash flow	-52791000	Operating Cash Flow: -52791000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g -53.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g)	Source evidence
20232023-12-31	Free cash flow	20177000	Operating Cash Flow: 21548000 Open source Capital Expenditure: 1371000 Open source
20242024-12-31	Free cash flow	-37811000	Operating Cash Flow: -36393000 Open source Capital Expenditure: 1418000 Open source
20252025-12-31	Free cash flow	-53811000	Operating Cash Flow: -52791000 Open source Capital Expenditure: 1020000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 28.12 million Exact value Exact value: -28119000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2023-01-01 – 2023-12-31: -28119000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source Share or cite Citation for Net Income · ProQR Therapeutics N.V. · 2023-12-31 ProQR Therapeutics N.V. (edgar:1612940) Net Income: -28119000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:NetIncome: -28119000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2001459 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 21.55 million Exact value Exact value: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2023-01-01 – 2023-12-31: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ProQR Therapeutics N.V. · 2023-12-31 ProQR Therapeutics N.V. (edgar:1612940) Operating Cash Flow: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:OperatingCashFlow: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2305311 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.37 million Exact value Exact value: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2023-01-01 – 2023-12-31: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ProQR Therapeutics N.V. · 2023-12-31 ProQR Therapeutics N.V. (edgar:1612940) Capital Expenditure: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:CapitalExpenditure: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2310948 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 20.18 million Calculation and evidence 21548000 − 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Exact free cash flow: 20177000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2023-01-01 – 2023-12-31: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ProQR Therapeutics N.V. · 2023-12-31 ProQR Therapeutics N.V. (edgar:1612940) Free cash flow: 20177000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 21548000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2305311 Filing: 000110465926026713 Input fundies:CapitalExpenditure: 1371000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2310948 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 27.76 million Exact value Exact value: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2024-01-01 – 2024-12-31: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source Share or cite Citation for Net Income · ProQR Therapeutics N.V. · 2024-12-31 ProQR Therapeutics N.V. (edgar:1612940) Net Income: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:NetIncome: -27763000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2000345 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 36.39 million Exact value Exact value: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2024-01-01 – 2024-12-31: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ProQR Therapeutics N.V. · 2024-12-31 ProQR Therapeutics N.V. (edgar:1612940) Operating Cash Flow: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:OperatingCashFlow: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2304445 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.42 million Exact value Exact value: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2024-01-01 – 2024-12-31: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ProQR Therapeutics N.V. · 2024-12-31 ProQR Therapeutics N.V. (edgar:1612940) Capital Expenditure: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:CapitalExpenditure: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2310163 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 37.81 million Calculation and evidence -36393000 − 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Exact free cash flow: -37811000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2024-01-01 – 2024-12-31: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ProQR Therapeutics N.V. · 2024-12-31 ProQR Therapeutics N.V. (edgar:1612940) Free cash flow: -37811000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36393000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2304445 Filing: 000110465926026713 Input fundies:CapitalExpenditure: 1418000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2310163 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 42.18 million Exact value Exact value: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2025-01-01 – 2025-12-31: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Net Income Open source Share or cite Citation for Net Income · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Net Income: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:NetIncome: -42184000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#1999231 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 52.79 million Exact value Exact value: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2025-01-01 – 2025-12-31: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Operating Cash Flow: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:OperatingCashFlow: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2303580 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 1.02 million Exact value Exact value: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2025-01-01 – 2025-12-31: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Capital Expenditure: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g&dimensions= Input fundies:CapitalExpenditure: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2309378 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 53.81 million Calculation and evidence -52791000 − 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Exact free cash flow: -53811000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g 2025-01-01 – 2025-12-31: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ProQR Therapeutics N.V. · 2025-12-31 ProQR Therapeutics N.V. (edgar:1612940) Free cash flow: -53811000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1612940?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52791000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2303580 Filing: 000110465926026713 Input fundies:CapitalExpenditure: 1020000 Unit_Standard_EUR_HsNxtFuUyE6B5yTe5VSF0g (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1612940/000110465926026713/prqr-20251231x20f.htm#2309378 Filing: 000110465926026713 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

206 filings · 4,707 latest values · 4,707 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001612940, 1612940, PRQR, edgar:1612940

Also known as ProQR Therapeutics B.V., ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation